Иресса
(Gefitinib)
(250 mg)
(thirty)
(Capsules)
Geftinat (gefitinib) 250 mg 30 caps. NATCO India
Article:
In Stock
Iress analogue, iresa
Indications
- Locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations in epidermal growth factor receptor tyrosine kinase
-
Commercial name:Иресса
-
Сhemical name:Gefitinib
-
Dosage:250 mg
-
Quantity:thirty
-
Release form:Capsules
No reviews yet